
OncLive News Network®
Series
All
All


Optimizing Outcomes in the Long-Term Management of Patients With AML
Catherine Lai, MD, MPH, discusses strategies for optimizing outcomes in the long-term management of Acute Myeloid Leukemia (AML), particularly for patients in first remission without a transplant. She also shares perspectives on updates from the 65th ASH Annual Meeting.

Evolving Treatment Strategies in Chronic Lymphocytic Leukemia: Insights From ASH 2023
Richard Furman, MD, and Chaitra S. Ujjani, MD, discuss the changing landscape of treatment strategies for patients with CLL, highlighting key updates presented at ASH 2023 and their potential implication on clinical practice.

Emerging Therapies in the Management of HR+, HER2- Metastatic Breast Cancer
Experts provides an in-depth review of current and emerging options for the treatment of HR+, HER2- metastatic breast cancer, including discussions around overcoming endocrine resistance, sequencing combination therapies, and optimizing quality of life and outcomes.

Optimizing Care Across the Continuum: Updates in the Detection and Treatment of Prostate Cancer
Expert oncologist discuss key data from 2023 on the detection and treatment of prostate cancer.

Advances in Hepatocellular Carcinoma (HCC): Key Updates from AASLD 2023 and Beyond
Anwaar Saeed, MD, and Amit Singal, MD, explore recent updates in the treatment of advanced hepatocellular carcinoma (HCC) presented at the 2023 AASLD: The Liver Meeting Congress and surrounding meetings.

Updates from IKCS 2023 and Surrounding Meetings in Advanced RCC
Brian Rini, MD, and Hans Hammers, MD, explore key data updates in the management of advanced renal cell carcinoma (RCC) presented at the 2023 IKCS: North America Congress and other recent meetings.

OncLive News Network: On Location at ASH 2023
Join us LIVE at this year's 2023 ASH Annual Meeting! OncLive® will broadcast a series of interviews with top thought leaders in hematologic malignancies, including chronic lymphocytic leukemia, acute lymphoblastic leukemia, myelodysplastic/myeloproliferative neoplasms, Hodgkin and non–Hodgkin lymphoma, multiple myeloma, and graft-vs-host-disease. The experts will share their insights and reactions to the pivotal data presented during the conference.

Post-Conference Perspectives Year in Review: 2023 Developments in Advanced or Recurrent Endometrial Cancer
Floor J. Backes, MD, and Matthew Powell, MD, explore key data updates in the management of advanced or recurrent endometrial cancer presented at the 2023 ESMO Congress and other recent meetings.

OncLive News Network: On Location at ESMO 2023
Join us LIVE at this year's 2023 ESMO Congress! OncLive® will broadcast a series of interviews with top thought leaders in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, and gynecologic malignancies. The experts will share their insights and reactions to the pivotal data presented during the conference.

Expert Perspectives on Diagnosis, Management, and Emerging Therapies in Low-Grade Serous Ovarian Cancer
Expert perspectives on the current diagnostic and treatment landscape for patients with low-grade serous ovarian cancer and how recent learnings have impacted real-world practice.

The Effects of Real-World Evidence on the Treatment of HER2+ mBC
Joseph Gligorov, MD, reviews advancements in the treatment of HER2-positive breast cancer, including the pivotal DESTINY-Breast03 study, global perspectives, sequencing strategies based on French real-world evidence, and the management of adverse events in advanced therapies.

Evolving Treatment Strategies in High-Risk Neuroblastoma
Giselle Sholler, MD, and Anurag Agrawal, MD, discuss the changing landscape of treatment strategies for patients with high-risk neuroblastoma and review key clinical trial data presented at the ASCO 2023 Annual Meeting.

Post-Conference Perspectives: Managing R/R B-ALL with CAR T-Cell Therapy
Jae Park, MD, reviews key data in the management of relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) recently presented at the ASCO 2023 Annual Meeting.

Post-Conference Perspectives: Recent Advances in the Management of Chronic GvHD
Preet M. Chaudhary, MD, PhD and Noah Merin, MD, PhD discuss the chronic graft versus host disease treatment landscape, covering first- and second-line treatments and emergent trial data.

Post-Conference Perspectives: Updates in HER2+ Metastatic Colorectal Cancer (mCRC); ASCO 2023 Highlights
Following the 2023 ASCO Annual Meeting, Tanios S. Bekaii-Saab, MD, discusses recent data updates and provides clinical insights on the evolving treatment landscape for metastatic colorectal cancer.

Post-Conference Perspectives: Updates in HER2+ Metastatic Breast Cancer; ASCO 2023 Highlights
Megan Kruse, MD, reviews updates from the 2023 ASCO Annual Meeting and offers insights onthe evolving treatment landscape for HER2+ metastatic breast cancer.

Post-Conference Perspectives: Advances in the Management of Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia
Updates in Philadelphia-positive acute lymphoblastic leukemia treatment are highlighted following ASCO 2023.

Updates in Chronic Lymphocytic Leukemia from the ICML 2023 Meeting and Beyond
Brian T. Hill MD, PhD, and Paulo Ghia, MD engage with recent data focusing on BTKis in CLL presented at the ICML 2023 Annual Meeting as well as how that data may be applied to clinical practice.

OncLive News Network: On Location at ASCO 2023
Join us LIVE at this year's 2023 ASCO Annual Meeting! OncLive® will broadcast a series of interviews with top thought leaders in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, gynecologic malignancies, melanoma, and sarcoma. The experts will share their insights and reactions to the pivotal data presented during the conference.

Post-Conference Perspectives: Updates in Colorectal Cancer: Highlights from ASCO GI 2023 and Beyond
Tanios S. Bekaii-Saab, MD, FACP describes the current colorectal cancer (CRC) treatment landscape, shares relevant updates from the American Society for Clinical Oncology’s Gastrointestinal Cancers Symposium 2023, and discusses his hopes for the future of the field.

Potential Role of Navitoclax in Myelofibrosis and T-Cell Acute Lymphoblastic Leukemia
Expert perspectives on the emerging role of navitoclax, a novel BCL-XL inhibitor, in the treatment armamentarium for myelofibrosis and T-cell acute lymphoblastic leukemia, respectively.

Post-Conference Perspectives: Updates on TIL Therapy for Solid Tumors, Including Melanoma and NSCLC
Expert perspectives from Amod Sarnaik, MD, and Krishna Komanduri, MD, on the evolving role of tumor-infiltrating lymphocyte therapy in solid tumors, following the Society for Immunotherapy of Cancer (SITC) 2022 meeting.

Emerging CAR-T Therapies in Large B-cell Lymphomas (LBCL): Highlights from ASH 2022 and Beyond
Experts review key updates in LBCL management from the ASH 2022 annual meeting.

Post-Conference Perspectives: CD19-directed CAR-T Cell Therapy in Lymphomas
Loretta J. Nastoupil, MD, and Marc S. Hoffman, MD, review key updates on the role of CAR T-cell therapy in large B-cell lymphoma (LBCL), follicular lymphoma, and non-Hodgkin’s lymphoma, and discuss how the data applies to clinical practice.

Targeted Approaches in Myelodysplastic Syndromes and Myelofibrosis
Experts on myelofibrosis and myelodysplastic syndromes discuss recent data updates, including those presented at the 2022 American Society of Hematology (ASH) Annual Meeting, and provide their outlook on the future of treatment for each.

Post-Conference Perspectives: 2022 San Antonio Breast Cancer Symposium Highlights
Charles E. Geyer, MD and Ian E. Krop, MD, PhD review current trends in the breast cancer treatment landscape, discuss new data presented at the 2022 San Antonio Breast Cancer Symposium as well as other major findings presented over the course of the year.

Gaining Ground: Expanding Options for Advanced HCC
Dr. Ghassan Abou-Alfa leads a small panel including Dr. Robert Lewandowksi and Dr. Amit Singal in a multidisciplinary discussion of hepatocellular carcinoma and updates to the treatment armamentarium.

Emerging First-Line Treatment Options for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
Harry Yoon, MD and Nabil Saba, MD, FACP, discuss recent data on novel regimens for first-line treatment of advanced/metastatic ESCC, including the immunotherapy regimen tislelizumab.

Updates in Advanced Renal Cell Carcinoma from The 2022 International Kidney Cancer Symposium
Hans Hammers, MD, PhD, and Moshe Ornstein, MD, MA, discuss data updates in advanced renal cell carcinoma (RCC) that were presented at the recent 2022 International Kidney Cancer Symposium.
